Phibro Animal Health to pursue patent protection for development of ASF vaccine
Phibro Animal Health announced it is pursuing patent protection following an advance in the on-going development of a vaccine for African Swine Fever, or ASF. This step in the vaccine development process involves the identification of immunogenic epitopes and proteins that show strong potential to form the basis for a vaccine against ASF. Phibro's R&D team and its collaborators made this identification through the use of a bioinformatics analysis tool in order to select for the highest potential epitopes and proteins capable of eliciting protective immune response. Phibro's approach is to create a specific epitope-based vaccine, rather than an attenuated live vaccine. If successful, this approach would not only be an effective response to ASF, but would result in a vaccine that presents no risk of further spreading the disease.